Mina Sooch, Ocuphire Pharma CEO
Oral drug for diabetic retinopathy flunks PhII, but biotech wants to go into PhIII with new endpoint
When you’re trying to develop the first oral treatment for diabetic patients with eye disease, a Phase II flop need not be the end of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
